GLP-1
-
Eli Lilly Surges After FDA Approves Foundayo Obesity Pill
Eli Lilly shares rose 4% following FDA approval of Foundayo, an oral GLP-1 medication for weight loss, signaling a major shift in the obesity treatment market.
-
GLP-1 Drugs Linked to Lower Colon Cancer Risk in New Study
New research presented at the 2026 ASCO Gastrointestinal Cancers Symposium suggests GLP-1 receptor agonists may reduce colorectal cancer incidence by 36% compared to aspirin.
-
Beyond Obesity: The Emerging Risks of GLP-1 Medications
As GLP-1 drugs gain popularity for weight loss, new studies highlight potential long-term risks for bone health and metabolism, sparking a debate on their role in modern medicine.
-
Novo Nordisk Boosts Oral GLP-1 Production Amid Intensifying Competition
Novo Nordisk commits €432 million to scale oral GLP-1 production in Ireland, solidifying its chronic disease treatment focus.
-
McDonald’s Reports Strong Q4 Amid 2026 Menu Shifts and Value Push
McDonald’s exceeded Q4 2025 sales and earnings expectations, driven by value promotions and marketing. The company is now adapting its 2026 menu for GLP-1 drug users, expanding McCafé offerings, and bringing back the popular Shamrock Shake.
-
Serena Williams Stars in Ro’s Super Bowl Ad, Highlighting GLP-1 Health Benefits
Ro’s first Super Bowl commercial, featuring Serena Williams, aims to shift the narrative around GLP-1 medications by showcasing their significant health benefits beyond weight loss, based on Williams’s personal experience.
-
Novo Nordisk CEO Unveils Aggressive Strategy to Reclaim GLP-1 Market Lead, Targets 2 Billion People
Novo Nordisk’s new CEO Maziar Mike Doustdar outlines a bold three-pronged strategy for 2026, aiming to reclaim market dominance in the GLP-1 obesity drug sector from rival Eli Lilly. The plan focuses on commercial execution, pipeline progression, and a return…
-
Ozempic Alternatives & Beyond: Unpacking Weight Loss Hype, Natural Options, and Sustainable Journeys
Explore the complex world of weight loss beyond Ozempic, from the potential of natural supplements like berberine to the transformative power of lifestyle changes, and the long-term challenges of maintaining results.
-
Wegovy Weight Loss: How GLP-1 Drugs Are Reshaping Midlife Health and What Comes Next
Wegovy and other GLP-1 weight loss drugs are transforming how midlife women address weight gain, but concerns about side effects, misuse, and long-term health persist. New oral GLP-1 pills may help maintain weight loss after injections, yet the debate over…
-
Serena Williams Reenters Tennis Testing Pool: Comeback Rumors, Retirement Realities, and the Next Chapter
Serena Williams has officially rejoined tennis’s anti-doping testing pool, igniting speculation about a possible return. Yet, the 23-time Grand Slam champion insists she’s not coming back, even as she navigates life after retirement and redefines her legacy both on and…
-
Weight Loss Medication in 2025: Safety, Shortages, and the Surge of Counterfeits
As breakthrough weight loss drugs reshape obesity treatment, 2025 brings new hope—and new risks. From FDA-approved injections to counterfeit dangers and WHO warnings about limited access, this deep dive reveals the realities behind the headlines.
-
Ozempic and GLP-1 Drugs: New Safety Warnings on Mental Health and Contraception Risks
Australian regulators have updated safety warnings for Ozempic and related GLP-1 drugs, citing potential mental health risks and contraceptive effectiveness concerns. While evidence of a direct link is inconclusive, authorities advise caution and closer monitoring for vulnerable patients.
-
Drug Use and Innovation: From GLP-1 Breakthroughs to the Shadows of MLB
This article explores two sides of the drug narrative in 2025: the scientific push to refine GLP-1 therapies for weight loss and the hidden, high-pressure world of prescription drug use among professional athletes, as revealed by court testimony in the…
-
Wegovy Weight Loss Drug Sees Major 30% Price Cut as Pharma Giants Respond to Pressure
Novo Nordisk has slashed Wegovy’s price by 30%, a move hailed as transformative for patient access. The decision follows mounting pressure from the Trump Administration to make weight loss and diabetes treatments more affordable.
-
Semaglutide Shows Promise in Treating Liver Disease MASH
A landmark phase 3 trial reveals semaglutide’s potential to treat metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions globally.